Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Marseille cedex, France Clinical Trials

A listing of Marseille cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (134) clinical trials

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase

4.59 miles

Learn More »

Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer

Pancreatic adenocarcinoma is the fifth leading cause of cancer related deaths in Western countries. The sole curative treatment is surgical resection. Unfortunately, curative surgery is possible in only 10 to 15 % of cases. In a palliative way, the remaining patients can be treated with chemotherapy in locally advanced (Gemcitabine) ...

Phase

4.59 miles

Learn More »

Study of Pharmacodynamics Pharmacokinetics Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

This study will investigate the safety and efficacy of VAY736 administered subcutaneously (s.c.) every 4 weeks for 48 weeks. Approximately, 84 subjects will be randomized in a 1:1 ratio on top of local standard of care (SOC), to receive VAY736 or placebo.

Phase

4.59 miles

Learn More »

Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

Several cohort studies have demonstrated that survival time in patients with untreated early stage prostate cancer is greater than 10 years in more than 70% of cases, suggesting the existence of slowly progressive or non-progressive forms of prostate cancer that would never cause any impairment to quality or quantity of ...

Phase

6.05 miles

Learn More »

Prospective Evaluation of the Ablation Therapy With Bipolar Radio Frequency for Nonresectable Bile Duct Cancer

90 % of the patients with bile duct cancer are not justifiable of a surgical resection with curative aim for oncologic reasons ( metastatic extensions), for reasons of resectability (canalar extension, vascular) or still for surgically reasons (age, comorbidity). The palliative care of these patients consists at first in assuring ...

Phase

6.05 miles

Learn More »

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799 MK-3475-799).

This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the ...

Phase

6.05 miles

Learn More »

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenia, especially anemia, and often evolving to Acute myeloblastic Leukemia (AML). Main prognostic factors of MDS, for progression to AML and survival, include the number and importance of cytopenias, percent marrow blasts and bone ...

Phase

6.05 miles

Learn More »

The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

Phase

6.05 miles

Learn More »

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Phase

6.05 miles

Learn More »

Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT

This is a phase 2, multicenter, open-label, single arm estimation study in adult subjects with high-risk DLBCL in complete remission. The study will consist of up to a 28-day screening period, a run-in period of up to 24 months, a 12-week treatment period (8 weeks of blinatumomab treatment followed by ...

Phase

6.05 miles

Learn More »